UBS raised the firm’s price target on BioMarin (BMRN) to $114 from $113 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- 3 Best Stocks to Buy Now, 8/5/2025, According to Top Analysts
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Pipeline Justify Buy Rating
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
- BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results
- Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities